Encorafenib, sold under the brand name Braftovi, is an anti-cancer medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.
{{Drugbox | image = Encorafenib.svg | image_class = skin-invert-image | width = 240 | alt = | caption =
| pronounce = | tradename = Braftovi | Drugs.com = | MedlinePlus = a618040 | DailyMedID = Encorafenib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = EC03 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).